ABBV · AbbVie Inc
Price
Snapshot
50 fields · last close| Market Cap | $504.4B |
| P/E | 79.93 |
| Float | 1.76B |
| Beta | 0.19 |
| Volatility | 5.0% |
| Exchange | NYSE |
| Sector | Biotechnology |
| Cap tier | Mega cap |
| Macro sensitivity | Low |
| Clavix score | 79.3 |
| Price | 283.64 |
| Change | −0.62% |
| Prev Close | 285.42 |
| Open | 283.61 |
| Day Low | 282.95 |
| Day High | 286.64 |
| Avg Vol | 6 |
| Avg $ Vol | $1.68B |
| 52W High | 291.40 |
| 52W Low | 190.75 |
| 52W Pos | 92.3% |
| From High | −2.66% |
| From Low | +48.70% |
| Max DD 1Y | −16.46% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | +5.08% |
| SMA 50 | +8.07% |
| SMA 200 | +21.32% |
| RSI (14) | 71.1 |
| Vol 30D | 20.2% |
| Vol 90D | 25.9% |
| 1Y Range | 191–291 |
| Daily bars | 743 |
| Perf Week | +3.24% |
| Perf Month | +8.11% |
| Perf Quarter | +12.65% |
| Perf Half Y | +40.11% |
| Perf Year | +25.81% |
| Perf YTD | +23.69% |
| Prev Day | −0.62% |
| Clavix | B+ |
| Debt / Eq | 20.19 |
| Curr Ratio | 0.67 |
| Int Cover | 4.2× |
| FCF Margin | 29.1% |
| Rev Growth | +8.6% |
| Profit | Profitable |
| Leverage | Very High |
| Sector rank | 5 / 35 |
What ABBV does
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions.
In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis.
Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation.
The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Clavix risk grade
regraded every trading dayABBV grades B+, 79.3 of 100. Steadiest on Price Stability (67), most exposed on News Sentiment (55, mixed). 1 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 5 of 35 in Biotechnology by Clavix score.
How rough the ride is
| ABBV | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.19 | 0.51 |
| Volatilityannualized | 5.0% | 14.6% |
| Max drawdown, past yearworst peak-to-trough fall | −16.5% | — |
| Typical daily movemedian absolute daily change | 0.95% | — |
| Days beyond ±3%of the last 252 sessions | 18 (7%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| ABBV | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.19 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| ABBV | |
|---|---|
| 1 week | +3.2% |
| 1 month | +8.1% |
| Year to date | +23.7% |
| 1 year | +25.8% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| ABBV | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 25 Sep |
| Average score0 most bearish, 100 most bullish | 67 |
| Bullish · bearisharticles above 60 · below 40 | 25 · 4 |
| Directionarticles whose tone is improving vs worsening | 25 ↑ 4 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| ABBV | |
|---|---|
| Revenue growthyear over year | +8.6% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openAbbVie reported Phase 2a results showing ABBV-466, an experimental dual-targeting antibody for Crohn's disease, produced higher rates of endoscopic remission (healing visible on a scope) than single-target therapies against IL-23 or α4β7 at 12 weeks, with the advantage growing by week 24. Tissue samples also showed signs of intestinal repair.
AbbVie and Genmab reported that epcoritamab combined with R-CHOP chemotherapy met its main goal in a Phase 3 trial for newly diagnosed high-risk diffuse large B-cell lymphoma (DLBCL), showing a statistically significant improvement in how long patients went without their disease worsening. Side effects matched what is already known about each drug. The result adds another late-stage cancer drug to AbbVie's pipeline alongside its immunology franchise.
An article comparing AbbVie and Altria as long-term dividend holdings notes that AbbVie cut its 2026 adjusted earnings-per-share guidance to a range of $13.76 to $13.96. The full article body was cut off, so further details are not available.
An analyst comparison piece argues Sanofi looks more attractive than AbbVie, citing Sanofi's upgraded 2026 outlook, Dupixent growth, and lower valuation, while noting Sanofi's pipeline setbacks and vaccine sales challenges.
AbbVie received two FDA Breakthrough Therapy Designations for its experimental cancer drug telisotuzumab adizutecan, aimed at biomarker-defined patient groups in colorectal cancer and non-small cell lung cancer. This marks the first Breakthrough Therapy status for the drug.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc | A- | $233.8B | 26.74 | 0.44 | Compare |
| GILD | Gilead Sciences, Inc | A- | $193.7B | 22.76 | 0.40 | Compare |
| VRTX | Vertex Pharmaceuticals Inc | B+ | $126.7B | 28.75 | 0.29 | Compare |
| MRNA | Moderna Inc | F | $87.04B | — | 1.17 | Compare |
| REGN | Regeneron Pharmaceuticals Inc | B+ | $81.41B | 18.81 | 0.13 | Compare |
| NTRA | Natera Inc | B- | $56.71B | — | 1.54 | Compare |
| RVMD | Revolution Medicines Inc | B- | $38.14B | — | 1.44 | Compare |
| BIIB | Biogen Inc | B+ | $34.37B | 41.19 | 0.10 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.